Loss of TP53 expression in immortalized Choroid plexus epithelial cells results in increased resistance to anticancer agents

Journal of Neuro-Oncology

Volumn 109, Issue 3, 2012, Pages 449-455

  Krzyzankova, Miroslava ^a   Mertsch, Sonja ^a   Koos, Björn ^a   Jeibmann, Astrid ^a   Kruse, Anne ^a   Kordes, Uwe ^b   Frühwald, Michael C ^a,c   Wolff, Johannes E ^d   Paulus, Werner ^a   Hasselblatt, Martin ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c KLINIKUM AUGSBURG   (Germany)

^d TUFTS MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Choroid plexus carcinoma; Pediatric brain tumor; TP53

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; KI 67 ANTIGEN; METHOTREXATE; PROTEIN P53; RAPAMYCIN; TEMOZOLOMIDE; VALPROIC ACID; VINCRISTINE;

ADOLESCENT; ARTICLE; CANCER RESISTANCE; CELL METABOLISM; CHILD; CHOROID PLEXUS TUMOR; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MALE; PRESCHOOL CHILD; PROTEIN EXPRESSION; SCHOOL CHILD; TP53 GENE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; CHOROID PLEXUS; CHOROID PLEXUS NEOPLASMS; DRUG RESISTANCE, NEOPLASM; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INFANT, NEWBORN; MALE; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84866013629     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0915-3     Document Type: Article

References (29)

1. Wolburg H, Paulus W (2010) Choroid plexus: biology and pathology. Acta Neuropathol 119:75-88
2. Paulus W, Brandner S (2007) Choroid plexus tumours. In: Louis DN, Ohgaki H, Wiestler O, Cavenee WK (eds) World Health Organization classification of tumors pathology and genetics of tumours of the nervous system. IARC Press, Lyon
3. Mazloom A, Wolff JE, Paulino AC (2010) The impact of radiotherapy fields in the treatment of patients with choroid plexus carcinoma. Int J Radiat Oncol Biol Phys 78:79-84
4. Wrede B, Liu P, Wolff JE (2007) Chemotherapy improves the survival of patients with choroid plexus carcinoma: a meta-analysis of individual cases with choroid plexus tumors. J Neurooncol 85:345-351 (Pubitemid 350142525)
5. Lafay-Cousin L, Mabbott DJ, Halliday W, Taylor MD, Tabori U, Kamaly-Asl ID, Kulkarni AV, Bartels U, Greenberg M, Bouffet E (2010) Use of ifosfamide, carboplatin, and etoposide chemotherapy in choroid plexus carcinoma. J Neurosurg Pediatr 5:615-621
6. Berrak SG, Liu DD, Wrede B, Wolff JE (2011) Which therapy works better in choroid plexus carcinomas? J Neurooncol 103:155-162
7. El-Deiry WS (2003) The role of p53 in chemosensitivity and radiosensitivity. Oncogene 22:7486-7495 (Pubitemid 37487171)
8. Tabori U, Shlien A, Baskin B, Levitt S, Ray P, Alon N, Hawkins C, Bouffet E, Pienkowska M, Lafay-Cousin L, Gozali A, Zhukova N, Shane L, Gonzalez I, Finlay J, Malkin D (2010) TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. J Clin Oncol 28:1995-2001
9. Wrede B, Hasselblatt M, Peters O, Thall PF, Kutluk T, Moghrabi A, Mahajan A, Rutkowski S, Diez B, Wang X, Pietsch T, Kortmann RD, Paulus W, Jeibmann A, Wolff JE (2009) Atypical choroid plexus papilloma: clinical experience in the CPT-SIOP-2000 study. J Neurooncol 95:383-392
10. Custodio G, Taques GR, Figueiredo BC, Gugelmin ES, Oliveira Figueiredo MM, Watanabe F, Pontarolo R, Lalli E, Torres LF (2011) Increased incidence of choroid plexus carcinoma due to the germline TP53 R337H mutation in southern Brazil. PLoS ONE 6:e18015
11. Gozali AE, Britt B, Shane L, Gonzalez I, Gilles F, McComb JG, Krieger MD, Lavey RS, Shlien A, Villablanca JG, Erdreich-Epstein A, Dhall G, Jubran R, Tabori U, Malkin D, Finlay JL (2012) Choroid plexus tumors: management, outcome, and association with the Li-Fraumeni syndrome: the Children's Hospital Los Angeles (CHLA) experience, 1991-2010. Pediatr Blood Cancer 58:905-909
12. Zheng W, Zhao Q (2002) Establishment and characterization of an immortalized Z310 choroidal epithelial cell line from murine choroid plexus. Brain Res 958:371-380 (Pubitemid 35441190)
13. Hasselblatt M, Böhm C, Tatenhorst L, Dinh V, Newrzella D, Keyvani K, Jeibmann A, Buerger H, Rickert CH, Paulus W (2006) Identification of novel diagnostic markers for choroid plexus tumors: a microarray-based approach. Am J Surg Pathol 30:66-74 (Pubitemid 43740211)
14. Judkins AR, Burger PC, Hamilton RL, Kleinschmidt-DeMasters B, Perry A, Pomeroy SL, Rosenblum MK, Yachnis AT, Zhou H, Rorke LB, Biegel JA (2005) INI1 protein expression distinguishes atypical teratoid/rhabdoid tumor from choroid plexus carcinoma. J Neuropathol Exp Neurol 64:391-397 (Pubitemid 40629129)
15. Tomm M, Koch A, Mertsch S, Wrede B, Jeibmann A, Wolff J, Paulus W, Hasselblatt M (2009) Role of Wnt inhibitory factor-1 and Wnt/wingless signaling in choroid plexus tumors. Pediatr Blood Cancer 53:1152-1155
16. Hasselblatt M, Mertsch S, Koos B, Riesmeier B, Stegemann H, Jeibmann A, Tomm M, Schmitz N, Wrede B, Wolff JE, Zheng W, Paulus W (2009) TWIST-1 is overexpressed in neoplastic choroid plexus epithelial cells and promotes proliferation and invasion. Cancer Res 69:2219-2223
17. Prasad P, Vasquez H, Das CM, Gopalakrishnan V, Wolff JE (2009) Histone acetylation resulting in resistance to methotrexate in choroid plexus cells. J Neurooncol 91:279-286
18. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63 (Pubitemid 14203433)
19. Bernal SD, Shapiro HM, Chen LB (1982) Monitoring the effect of anti-cancer drugs on L1210 cells by a mitochondrial probe, rhodamine-123. Int J Cancer 30:219-224 (Pubitemid 12055845)
20. Weyermann J, Lochmann D, Zimmer A (2005) A practical note on the use of cytotoxicity assays. Int J Pharm 288:369-376 (Pubitemid 40038590)
21. Gieni RS, Li Y, HayGlass KT (1995) Comparison of [3H]thymidine incorporation with MTT-and MTS-based bioassays for human and murine IL-2 and IL-4 analysis. Tetrazolium assays provide markedly enhanced sensitivity. J Immunol Methods 187:85-93 (Pubitemid 3002277)
22. Olivier M, Petitjean A, Marcel V, Petre A, Mounawar M, Plymoth A, de Fromentel CC, Hainaut P (2009) Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Ther 16:1-12
23. Lünenburger H, Lanvers-Kaminsky C, Lechtape B, Frühwald MC (2010) Systematic analysis of the antiproliferative effects of novel and standard anticancer agents in rhabdoid tumor cell lines. Anticancer Drugs 21:514-522
24. Weller M (1998) Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res 292:435-445 (Pubitemid 28282455)
25. Lu C, El-Deiry WS (2009) Targeting p53 for enhanced radio-and chemo-sensitivity. Apoptosis 14:597-606
26. Tabori U, Baskin B, Shago M, Alon N, Taylor MD, Ray PN, Bouffet E, Malkin D, Hawkins C (2010) Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol 28:1345-1350
27. Gessi M, von Bueren AO, Rutkowski S, Pietsch T (2012) p53 expression predicts dismal outcome for medulloblastoma patients with metastatic disease. J Neurooncol 106:135-141
28. Meley D, Spiller DG, White MR, McDowell H, Pizer B, See V (2010) p53-mediated delayed NF-kappaB activity enhances etoposideinduced cell death in medulloblastoma. Cell Death Dis 1:e41
29. Ma CX, Cai S, Li S, Ryan CE, Guo Z, Schaiff WT, Lin L, Hoog J, Goiffon RJ, Prat A, Aft RL, Ellis MJ, Piwnica-Worms H (2012) Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J Clin Invest 122:1541-1552